KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Return on Sales (2016 - 2026)

NovoCure's Return on Sales history spans 13 years, with the latest figure at 0.0% for Q1 2026.

  • On a quarterly basis, Return on Sales changed 0.0% to 0.0% in Q1 2026 year-over-year; TTM through Mar 2026 was 0.0%, a 0.0% change, with the full-year FY2025 number at 0.0%, changed 0.0% from a year prior.
  • Return on Sales hit 0.0% in Q1 2026 for NovoCure, down from 0.0% in the prior quarter.
  • Over the last five years, Return on Sales for NVCR hit a ceiling of 0.0% in Q1 2022 and a floor of 0.0% in Q2 2023.
  • Historically, Return on Sales has averaged 0.0% across 5 years, with a median of 0.0% in 2025.
  • The widest YoY moves for Return on Sales: up 0bps in 2022, down 0bps in 2022.
  • Tracing NVCR's Return on Sales over 5 years: stood at 0.0% in 2022, then dropped by -21bps to 0.0% in 2023, then fell by -16bps to 0.0% in 2024, then soared by 66bps to 0.0% in 2025, then tumbled by -191bps to 0.0% in 2026.
  • Business Quant data shows Return on Sales for NVCR at 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.